TLDR:
- Loyal, a biotech company developing drugs for dogs, raised $45M in Series B funding.
- The funding will support the development of products aimed at extending the lifespan and quality of life of dogs.
Article Summary:
Loyal, a San Francisco-based biotech company, recently secured $45 million in Series B funding, bringing their total funding to $125 million. The funding round was led by Bain Capital Ventures, with participation from other investors like Khosla Ventures and First Round Capital. The company plans to use the funds to continue developing drugs for dogs, with an expected product launch in early 2025, pending FDA approval.
CEO Celine Halioua expressed the company’s dedication to giving dogs longer, healthier lives through their drug development efforts. Loyal is focused on targeting the underlying mechanisms of aging in dogs to extend their lifespan and maintain their quality of life as they age. Currently, the company has three drugs in development, each targeting specific age groups and sizes of dogs.
The company’s vision is challenging but important, and they are excited to work with both new and existing investors to make FDA-approved dog longevity drugs a reality. This funding will enable Loyal to further their research and development efforts to benefit the health and well-being of dogs.
